Andrew Asberry

Andrew Asberry is a Bioanalytical Development Lead with extensive experience in oncology bioanalytical strategy and clinical research. They have held positions at prominent organizations including AstraZeneca and Sanofi, focusing on innovative therapeutic approaches and drug development. With a PhD in Medicinal Chemistry and Molecular Pharmacology from Purdue University and a background in both academia and industry, Andrew has contributed to patent applications, publications, and community engagement in the scientific field. Their expertise spans molecular biology, protein biochemistry, and regulatory knowledge, equipping them to effectively collaborate with clinical and research stakeholders.